Document:

Registrant's Management Incentive Plan

 Exhibit 10.2 
 VARIAN MEDICAL SYSTEMS, INC. 
 MANAGEMENT INCENTIVE PLAN 
 (Amended as of November 17, 2006) 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	 SECTION 1
	  	 BACKGROUND, PURPOSE AND DURATION
	  	B-1
	 1.1
	  	 Effective Date
	  	B-1
	 1.2
	  	 Purpose Of The Plan
	  	B-1
	 SECTION 2
	  	 DEFINITIONS
	  	B-1
	 2.1
	  	 “Actual Award”
	  	B-1
	 2.2
	  	 “Affiliate”
	  	B-1
	 2.3
	  	 “Base Salary”
	  	B-1
	 2.4
	  	 “Board”
	  	B-1
	 2.5
	  	 “Code”
	  	B-1
	 2.6
	  	 “Committee”
	  	B-1
	 2.7
	  	 “Company”
	  	B-1
	 2.8
	  	 “Disability”
	  	B-1
	 2.9
	  	 “EBIT”
	  	B-1
	 2.10
	  	 “EBITDA”
	  	B-1
	 2.11
	  	 “Earnings Per Share”
	  	B-2
	 2.12
	  	 “Employee”
	  	B-2
	 2.13
	  	 “Fiscal Year”
	  	B-2
	 2.14
	  	 “Maximum Award”
	  	B-2
	 2.15
	  	 “Net Income”
	  	B-2
	 2.16
	  	 “Net Orders”
	  	B-2
	 2.17
	  	 “Operating Cash Flow”
	  	B-2
	 2.18
	  	 “Participant”
	  	B-2
	 2.19
	  	 “Payout Formula”
	  	B-2
	 2.20
	  	 “Performance Goals”
	  	B-2
	 2.21
	  	 “Performance Period”
	  	B-2
	 2.22
	  	 “Plan”
	  	B-2
	 2.23
	  	 “Retirement”
	  	B-3
	 2.24
	  	 “Return on Assets”
	  	B-3
	 2.25
	  	 “Return on Equity”
	  	B-3
	 2.26
	  	 “Return on Sales”
	  	B-3
	 2.27
	  	 “Revenue”
	  	B-3
	 2.28
	  	 “Shareholder Return”
	  	B-3
	 2.29
	  	 “Shares”
	  	B-3
	 2.30
	  	 “Target Award”
	  	B-3
	 2.31
	  	 “VAI”
	  	B-3
	 SECTION 3
	  	 SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS
	  	B-3
	 3.1
	  	 Selection of Participants
	  	B-3
	 3.2
	  	 Determination of Performance Goals
	  	B-3
	 3.3
	  	 Determination of Target Awards
	  	B-3
	 3.4
	  	 Determination of Payout Formula or Formulae
	  	B-3
	 3.5
	  	 Determination of Actual Awards
	  	B-3
	 SECTION 4
	  	 PAYMENT OF AWARDS
	  	B-4
	 4.1
	  	 Right to Receive Payment
	  	B-4
	 4.2
	  	 Timing of Payment
	  	B-4
	 4.3
	  	 Form of Payment
	  	B-4
	 4.4
	  	 Payment in the Event of Death
	  	B-4

  

 B-i 

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page
	 SECTION 5
	  	 ADMINISTRATION
	  	B-4
	 5.1
	  	 Committee is the Administrator
	  	B-4
	 5.2
	  	 Committee Authority
	  	B-4
	 5.3
	  	 Decisions Binding.
	  	B-4
	 5.4
	  	 Delegation by the Committee.
	  	B-4
	 SECTION 6
	  	 GENERAL PROVISIONS
	  	B-5
	 6.1
	  	 Tax Withholding
	  	B-5
	 6.2
	  	 No Effect on Employment or Service
	  	B-5
	 6.3
	  	 Participation
	  	B-5
	 6.4
	  	 Indemnification
	  	B-5
	 6.5
	  	 Successors
	  	B-5
	 6.6
	  	 Beneficiary Designations
	  	B-5
	 6.7
	  	 Nontransferability of Awards
	  	B-5
	 6.8
	  	 Deferrals
	  	B-5
	 SECTION 7
	  	 AMENDMENT, TERMINATION AND DURATION
	  	B-6
	 7.1
	  	 Amendment, Suspension or Termination
	  	B-6
	 7.2
	  	 Duration of the Plan
	  	B-6
	 SECTION 8
	  	 LEGAL CONSTRUCTION
	  	B-6
	 8.1
	  	 Gender and Number
	  	B-6
	 8.2
	  	 Severability
	  	B-6
	 8.3
	  	 Requirements of Law
	  	B-6
	 8.4
	  	 Governing Law
	  	B-6
	 8.5
	  	 Captions
	  	B-6
	 EXECUTION
	  	B-6

  

 B-ii 

 VARIAN MEDICAL SYSTEMS, INC. 
 MANAGEMENT INCENTIVE PLAN 
 (Amended as of November 17, 2006)

 SECTION 1 
 BACKGROUND, PURPOSE AND DURATION 
 1.1    Effective Date.    This amended and
restated Plan is effective as of the date on which VAI distributes shares of the common stock of Varian, Inc. and Varian Semiconductor Equipment Associates, Inc. to the stockholders of VAI, subject to the approval of the Plan by a majority of the
shares of the common stock of VAI which are present in person or by proxy and entitled to vote at the 1999 Annual and Special Meeting of Stockholders of VAI. 
 1.2    Purpose of the Plan.    The Plan is intended to increase shareholder value and the success of the Company by motivating key executives (1) to perform to the
best of their abilities, and (2) to achieve the Company’s objectives. The Plan’s goals are to be achieved by providing such executives with incentive awards based on the achievement of goals relating to the performance of the Company
and its business units. The Plan is intended to permit the grant of awards that qualify as performance-based compensation under section 162(m) of the Code. 
 SECTION 2 
 DEFINITIONS 
 The following words and phrases shall have the following meanings unless a different meaning is plainly required by the context: 
 2.1    “Actual Award” means as to any Performance Period, the actual award (if any) payable to a Participant for the
Performance Period. Each Actual Award is determined by the Payout Formula for the Performance Period, subject to the Committee’s authority under Section 3.5 to reduce the award otherwise determined by the Payout Formula. 
 2.2    “Affiliate” means any corporation or other entity (including, but not limited to, partnerships and joint
ventures) controlling, controlled by, or under common control with the Company. 
 2.3    “Base Salary”
means as to any Performance Period, the Participant’s annualized salary rate on the last day of the Performance Period. Such Base Salary shall be before both (a) deductions for taxes or benefits, and (b) deferrals of compensation
pursuant to Company-sponsored plans. 
 2.4    “Board” means the Board of Directors of the Company.

 2.5    “Code” means the Internal Revenue Code of 1986, as amended. Reference to a specific section of
the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated thereunder, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or
regulation. 
 2.6    “Committee” means the committee appointed by the Board (pursuant to
Section 5.1) to administer the Plan. 
 2.7    “Company” means Varian Medical Systems, Inc., a
Delaware corporation, or any successor thereto. 
 2.8    “Disability” means a permanent and total
disability determined in accordance with uniform and nondiscriminatory standards adopted by the Committee from time to time. 
 2.9    “EBIT” means as to any Performance Period, the Company’s or a business unit’s income before reductions for interest and taxes, determined in accordance with generally accepted accounting
principles. 
 2.10    “EBITDA” means as to any Performance Period, the Company’s or a business
unit’s income before reductions for interest, taxes, depreciation and amortization, determined in accordance with generally accepted accounting principles. 
  

 B-1 

 2.11    “Earnings Per Share” means as to any Performance Period, the
Company’s or a business unit’s Net Income, divided by a weighted average number of common shares outstanding and dilutive common equivalent shares deemed outstanding, determined in accordance with generally accepted accounting principles.

 2.12    “Employee” means any employee of the Company or of an Affiliate, whether such employee is so
employed at the time the Plan is adopted or becomes so employed subsequent to the adoption of the Plan. 
 2.13    “Fiscal Year” means any fiscal year of the Company. 
 2.14    “Maximum Award” means as to any Actual Award to any Participant for any Performance Period, the lesser of two hundred percent (200%) of Base Salary or $2 million. 
 2.15    “Net Income” means as to any Performance Period, the Company’s or a business unit’s income after
taxes, determined in accordance with generally accepted accounting principles. 
 2.16    “Net Orders”
means as to any Performance Period, the Company’s or a business unit’s net orders calculated (and reviewed by the Company’s external independent auditors in accordance with agreed standard procedures) for and reported in the
Company’s quarterly financial earnings press release filed by the Company on a Current Report on Form 8-K. 
 2.17    “Operating Cash Flow” means as to any Performance Period, the Company’s or a business unit’s sum of Net Income plus depreciation and amortization less capital expenditures plus changes
in working capital comprised of accounts receivable, inventories, other current assets, trade accounts payable, accrued expenses, product warranty, advance payments from customers and long-term accrued expenses, determined in accordance with
generally acceptable accounting principles. 
 2.18    “Participant” means as to any Performance Period,
an Employee who has been selected by the Committee for participation in the Plan for that Performance Period. 
 2.19    “Payout Formula” means as to any Performance Period, the formula or payout matrix established by the Committee pursuant to Section 3.4 in order to determine the Actual Awards (if any) to be
paid to Participants. The formula or matrix may differ from Participant to Participant. 
 2.20    “Performance
Goals” means the goal(s) (or combined goal(s)) determined by the Committee (in its discretion) to be applicable to a Participant for a Target Award for a Performance Period. As determined by the Committee, the Performance Goals for any
Target Award applicable to a Participant may provide for a targeted level or levels of achievement using one or more of the following measures: (a) EBIT, (b) EBITDA, (c) Earnings Per Share, (d) Net Income, (e) Operating Cash
Flow, (f) Return on Assets, (g) Return on Equity, (h) Return on Sales, (i) Revenue, (j) Shareholder Return, (k) orders or Net Orders, (l) expenses, (m) cost of goods sold, (n) profit/loss or profit
margin, (o) working capital, (p) operating income, (q) cash flow, (r) market share, (s) return on equity, (t) economic value add, (u) stock price of the Company’s stock, (v) price/earning ratio,
(w) debt or debt-to-equity ratio, (x) accounts receivable, (y) cash, (z) write-off, (aa) assets, (bb) liquidity, (cc) operations, (dd) intellectual property (e.g., patents), (ee) product development, (ff) regulatory activities,
(gg) manufacturing, production or inventory, (hh) mergers, acquisitions or divestitures, (ii) financings, (jj) days sales outstanding, (kk) backlog, (ll) deferred revenue, and (mm) employee headcount. The Performance Goals may differ from
Participant to Participant and from award to award. Prior to the Determination Date, the Committee shall determine whether any significant element(s) shall be included in or excluded from the calculation of any Performance Goal with respect to any
Participants. “Determination Date” means the latest possible date that will not jeopardize a Target Award’s qualification as performance-based compensation under section 162(m) of the Code. 
 2.21    “Performance Period” means any fiscal period not to exceed three consecutive Fiscal Years, as determined by
the Committee in its sole discretion. 
 2.22    “Plan” means the Varian Medical Systems, Inc. Management
Incentive Plan, as set forth in this instrument and as hereafter amended from time to time. 
  

 B-2 

 2.23    “Retirement” means, with respect to any Participant,
“Retirement” as defined by the Company’s Retirement Policies, as they may be established from time to time. 
 2.24    “Return on Assets” means as to any Performance Period, the percentage equal to the Company’s or a business unit’s EBIT before incentive compensation, divided by average net Company or
business unit, as applicable, assets, determined in accordance with generally accepted accounting principles. 
 2.25    “Return on Equity” means as to any Performance Period, the percentage equal to the Company’s Net Income divided by average stockholder’s equity, determined in accordance with
generally accepted accounting principles. 
 2.26    “Return on Sales” means as to any Performance
Period, the percentage equal to the Company’s or a business unit’s EBIT before incentive compensation, divided by the Company’s or the business unit’s, as applicable, Revenue, determined in accordance with generally accepted
accounting principles. 
 2.27    “Revenue” means as to any Performance Period, the Company’s or a
business unit’s net sales, determined in accordance with generally accepted accounting principles. 
 2.28    “Shareholder Return” means as to any Performance Period, the total return (change in share price plus reinvestment of any dividends) of a Share. 
 2.29    “Shares” means shares of the Company’s common stock, $1.00 par value. 
 2.30    “Target Award” means the target award payable under the Plan to a Participant for the Performance Period,
expressed as a percentage of his or her Base Salary, as determined by the Committee in accordance with Section 3.3. 
 2.31    “VAI” means Varian Associates, Inc., a Delaware corporation. 
 SECTION 3

 SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS 
 3.1    Selection of Participants.    The Committee, in its sole discretion, shall select the Employees of
the Company who shall be Participants for any Performance Period. Participation in the Plan is in the sole discretion of the Committee, and on a Performance Period by Performance Period basis. Accordingly, an Employee who is a Participant for a
given Performance Period in no way is guaranteed or assured of being selected for participation in any subsequent Performance Period or Periods. 
 3.2    Determination of Performance Goals.    The Committee, in its sole discretion, shall establish the Performance Goals for each Participant for the Performance Period. Such Performance
Goals shall be set forth in writing. 
 3.3    Determination of Target Awards.    The
Committee, in its sole discretion, shall establish a Target Award for each Participant. Each Participant’s Target Award shall be determined by the Committee in its sole discretion, and each Target Award shall be set forth in writing.

 3.4    Determination of Payout Formula or Formulae.    On or prior to the Determination
Date, the Committee, in its sole discretion, shall establish a Payout Formula or Formulae for purposes of determining the Actual Award (if any) payable to each Participant. Each Payout Formula shall (a) be in writing, (b) be based on a
comparison of actual performance to the Performance Goals, (c) provide for the payment of a Participant’s Target Award if the Performance Goals for the Performance Period are achieved, and (d) provide for an Actual Award greater than
or less than the Participant’s Target Award, depending upon the extent to which actual performance exceeds or falls below the Performance Goals. Notwithstanding the preceding, no Participant’s Actual Award under the Plan may exceed his or
her Maximum Award. 
 3.5    Determination of Actual Awards.    After the end of each
Performance Period, the Committee shall certify in writing the extent to which the Performance Goals applicable to each Participant for the Performance Period were achieved or exceeded. The Actual Award for each Participant shall be determined by
applying the 

  

 B-3 

 
Payout Formula to the level of actual performance which has been certified by the Committee. Notwithstanding any contrary provision of the Plan, the
Committee, in its sole discretion, may (a) eliminate or reduce the Actual Award payable to any Participant below that which otherwise would be payable under the Payout Formula, and (b) determine what Actual Award, if any, will be paid in
the event of a termination of employment prior to the end of the Performance Period. The total aggregate Actual Awards under the Plan with respect to any Performance Period shall not exceed eight percent (8%) of the Company’s EBIT (but
before incentive compensation) for the most recent completed Fiscal Year. If the total aggregate Actual Awards with respect to a Performance Period would exceed this aggregate limit, all such Actual Awards shall be pro-rated on an equal basis among
all Participants according to a formula established by the Committee. 
 SECTION 4 
 PAYMENT OF AWARDS 
 4.1    Right to Receive Payment.    Each Actual Award that may become payable under the Plan shall be paid solely from the general assets of the Company. Nothing in this Plan shall be construed
to create a trust or to establish or evidence any Participant’s claim of any right other than as an unsecured general creditor with respect to any payment to which he or she may be entitled. 
 4.2    Timing of Payment.    Payment of each Actual Award shall be made within 120 days after the end of
the Performance Period during which the Award was earned. 
 4.3    Form of Payment.    Each
Actual Award normally shall be paid in cash (or its equivalent) in a single lump sum. However, the Committee, in its sole discretion, may declare any Actual Award, in whole or in part, payable in stock granted under the Company’s Omnibus Stock
Plan. The number of Shares granted shall be determined by dividing the cash amount foregone by the fair market value of a Share on the date that the cash payment otherwise would have been made. For this purpose, “fair market value” shall
mean the closing price on the Nasdaq National Market for the day in question. 
 4.4    Payment in the Event of
Death.    If a Participant dies prior to the payment of an Actual Award earned by him or her prior to death for a prior Performance Period, the Award shall be paid to his or her estate. 
 SECTION 5 
 ADMINISTRATION

 5.1    Committee is the Administrator.    The Plan shall be administered by the
Committee. The Committee shall consist of not less than two (2) members of the Board. The members of the Committee shall be appointed from time to time by, and serve at the pleasure of, the Board. Each member of the Committee shall qualify as
an “outside director” under section 162(m) of the Code. If it is later determined that one or more members of the Committee do not so qualify, actions taken by the Committee prior to such determination shall be valid despite such
failure to qualify. 
 5.2    Committee Authority.    It shall be the duty of the Committee to
administer the Plan in accordance with the Plan’s provisions. The Committee shall have all powers and discretion necessary or appropriate to administer the Plan and to control its operation, including, but not limited to, the power to
(a) determine which Employees shall be granted awards, (b) prescribe the terms and conditions of awards, (c) interpret the Plan and the awards, (d) adopt such procedures and subplans as are necessary or appropriate to permit
participation in the Plan by Employees who are foreign nationals or employed outside of the United States, (e) adopt rules for the administration, interpretation and application of the Plan as are consistent therewith, and (f) interpret,
amend or revoke any such rules. 
 5.3    Decisions Binding.    All determinations and
decisions made by the Committee, the Board, and any delegate of the Committee pursuant to the provisions of the Plan shall be final, conclusive, and binding on all persons, and shall be given the maximum deference permitted by law. 
 5.4    Delegation by the Committee.    The Committee, in its sole discretion and on such terms and
conditions as it may provide, may delegate all or part of its authority and powers under the Plan to one or more 

  

 B-4 

 
directors and/or officers of the Company; provided, however, that the Committee may delegate its authority and powers only with respect to awards that are
not intended to qualify as performance-based compensation under section 162(m) of the Code. 
 SECTION 6 
 GENERAL PROVISIONS 
 6.1    Tax Withholding.    The Company shall withhold all applicable taxes from any Actual Award, including any federal, state and local taxes (including the Participant’s FICA
obligation). 
 6.2    No Effect on Employment or Service.    Nothing in the Plan shall
interfere with or limit in any way the right of the Company to terminate any Participant’s employment or service at any time, with or without cause. For purposes of the Plan, transfer of employment of a Participant between the Company and any
one of its Affiliates (or between Affiliates) shall not be deemed a Termination of Service. Employment with the Company and its Affiliates is on an at-will basis only. The Company expressly reserves the right, which may be exercised at any time and
without regard to when during a Performance Period such exercise occurs, to terminate any individual’s employment with or without cause, and to treat him or her without regard to the effect which such treatment might have upon him or her as a
Participant. 
 6.3    Participation.    No Employee shall have the right to be selected to
receive an award under this Plan, or, having been so selected, to be selected to receive a future award. 
 6.4    Indemnification.    Each person who is or shall have been a member of the Committee, or of the Board, shall be indemnified and held harmless by the Company against and from (a) any
loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by
reason of any action taken or failure to act under the Plan or any award, and (b) from any and all amounts paid by him or her in settlement thereof, with the Company’s approval, or paid by him or her in satisfaction of any judgment in any
such claim, action, suit, or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The
foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Certificate of Incorporation or Bylaws, by contract, as a matter of law, or otherwise, or
under any power that the Company may have to indemnify them or hold them harmless. 
 6.5    Successors.    All obligations of the Company under the Plan, with respect to awards granted hereunder, shall be binding on any successor to the Company, whether the existence of such
successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business or assets of the Company. 
 6.6    Beneficiary Designations.    If permitted by the Committee, a Participant under the Plan may name a beneficiary or beneficiaries to whom any vested but unpaid
award shall be paid in the event of the Participant’s death. Each such designation shall revoke all prior designations by the Participant and shall be effective only if given in a form and manner acceptable to the Committee. In the absence of
any such designation, any vested benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s estate. 
 6.7    Nontransferability of Awards.    No award granted under the Plan may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will, by the laws of
descent and distribution, or to the limited extent provided in Section 6.6. All rights with respect to an award granted to a Participant shall be available during his or her lifetime only to the Participant. 
 6.8    Deferrals.    The Committee, in its sole discretion, may permit a Participant to defer receipt of
the payment of cash that would otherwise be delivered to a Participant under the Plan. Any such deferral elections shall be subject to such rules and procedures as shall be determined by the Committee in its sole discretion. 
  

 B-5 

 SECTION 7 
 AMENDMENT, TERMINATION AND DURATION 
 7.1    Amendment, Suspension or
Termination.    The Board, in its sole discretion, may amend or terminate the Plan, or any part thereof, at any time and for any reason. The amendment, suspension or termination of the Plan shall not, without the consent of
the Participant, alter or impair any rights or obligations under any Target Award theretofore granted to such Participant. No award may be granted during any period of suspension or after termination of the Plan. 
 7.2    Duration of the Plan.    The Plan shall commence on the date specified herein, and subject to
Section 7.1 (regarding the Board’s right to amend or terminate the Plan), shall remain in effect thereafter. 
 SECTION 8

 LEGAL CONSTRUCTION 
 8.1    Gender and Number.    Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural shall include the singular and the
singular shall include the plural. 
 8.2    Severability.    In the event any provision of the
Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included.

 8.3    Requirements of Law.    The granting of awards under the Plan shall be subject to all
applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. 
 8.4    Governing Law.    The Plan and all awards shall be construed in accordance with and governed by the laws of the State of California, but without regard to its conflict of law provisions.

 8.5    Captions.    Captions are provided herein for convenience only, and shall not serve
as a basis for interpretation or construction of the Plan. 
 EXECUTION 
 IN WITNESS WHEREOF, Varian Medical Systems, Inc., by its duly authorized officer, has executed the Plan on the date indicated below. 
  

									
		 		 	VARIAN MEDICAL SYSTEMS, INC.
					
	Dated: 	 	February 15, 2007	 		 	By: 	 	/s/ John W. Kuo
		 		 		 		 	 John W. Kuo
 Corporate Vice
President,
 General Counsel & Secretary

  

 B-6Underwriting Agreement

 Exhibit 10.1 
  
 Epicor Software Corporation 
 $200,000,000 Principal Amount 
 2.375% Convertible Senior Notes due 2027 
 Underwriting Agreement 
 May 2,
2007 
  

 UNDERWRITING AGREEMENT 
 May 2, 2007 
 UBS Securities LLC 
 Lehman Brothers Inc. 
     as Representatives of
the Underwriters 
 c/o UBS Securities LLC 
 299 Park Avenue

 New York, New York 10171-0026 
 Ladies and Gentlemen:

 Epicor Software Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters (the
“Underwriters”) named in Schedule A annexed hereto for whom you are acting as representatives (the “Representatives”), $200,000,000 aggregate principal amount of the Company’s 2.375% Senior Convertible
Notes due 2027 (the “Firm Notes”). In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional $30,000,000 aggregate
principal amount of the Company’s 2.375% Senior Convertible Notes due 2027 (the “Additional Notes”). The Firm Notes and the Additional Notes are hereinafter collectively sometimes referred to as the “Notes.”

 The Notes are to be issued pursuant to an indenture (the “Indenture”) to be dated as of May 8, 2007, between the
Company and U.S. Bank National Association, as trustee (the “Trustee”). The Notes will be convertible in accordance with their terms and the terms of the Indenture into cash and, if applicable, shares of the common stock (the
“Common Stock”) of the Company, $0.001 par value per share (the “Shares”). 
 The Notes and the Shares are
described in the Prospectus which is referred to below. 
 The Company has prepared and filed, in accordance with the provisions of the
Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Act”), with the Securities and Exchange Commission (the “Commission”) a registration statement on Form “S-3”
(File No. 333-142523) under the Act (the “registration statement”), including a prospectus, which registration statement registers the offer and sale of the Notes and Shares under the Act and incorporates by reference documents
which the Company has filed, or will file, in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange Act”). Such registration
statement has become effective under the Act. 
 Except where the context otherwise requires, “Registration Statement,” as
used herein, means the registration statement, as amended at the time of such registration statement’s effectiveness for purposes of Section 11 of the Act, as such section applies to the respective 
  

 Underwriters (the “Effective Time”), including (i) all documents filed as a part thereof or
incorporated or deemed to be incorporated by reference therein, (ii) any information contained or incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Act, to the extent such information is
deemed, pursuant to Rule 430B or Rule 430C under the Act, to be part of the registration statement at the Effective Time, and (iii) any registration statement filed to register the offer and sale of the Notes pursuant to Rule 462(b) under the
Act. 
 The Company has furnished to you, for use by the Underwriters and by dealers in connection with the offering of the Notes, copies of
one or more preliminary prospectus supplements relating to the Notes. Except where the context otherwise requires, “Pre-Pricing Prospectus,” as used herein, means each such preliminary prospectus supplement, in the form so
furnished, including any basic prospectus (whether or not in preliminary form) furnished to you by the Company and attached to or used with such preliminary prospectus supplement. Except where the context otherwise requires, “Basic
Prospectus,” as used herein, means any such basic prospectus and any basic prospectus furnished to you by the Company and attached to or used with the Prospectus Supplement (as defined below). 
 Except where the context otherwise requires, “Prospectus Supplement,” as used herein, means the final prospectus supplement, relating to
the Notes, filed by the Company with the Commission pursuant to Rule 424(b) under the Act on or before the second business day after the date hereof (or such earlier time as may be required under the Act), in the form furnished by the Company to you
for use by the Underwriters and by dealers in connection with the offering of the Notes. 
 Except where the context otherwise requires,
“Prospectus,” as used herein, means the Prospectus Supplement together with the Basic Prospectus attached to or used with the Prospectus Supplement. 
 “Permitted Free Writing Prospectuses,” as used herein, means the documents listed on Schedule B attached hereto and each “road show” (as defined in Rule 433 under the Act), if any,
related to the offering of the Notes contemplated hereby that is a “written communication” (as defined in Rule 405 under the Act). The Underwriters have not offered or sold and will not offer or sell, without the Company’s consent,
any Notes by means of any “free writing prospectus” (as defined in Rule 405 under the Act) that is required to be filed by the Underwriters with the Commission pursuant to Rule 433 under the Act, other than a Permitted Free Writing
Prospectus and customary notices in respect of the offering of the Notes through the Bloomberg system. 
 “Disclosure
Package,” as used herein, means any Pre-Pricing Prospectus or Basic Prospectus, in either case together with any combination of one or more of the Permitted Free Writing Prospectuses, if any. 
 Any reference herein to the registration statement, the Registration Statement, any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus
Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein (the “Incorporated  

  

 - 2 - 

 
Documents”), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any
reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement, any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus Supplement, the
Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the initial effective date of the Registration Statement, or the date of such Basic Prospectus,
such Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus or such Permitted Free Writing Prospectus, as the case may be, and deemed to be incorporated therein by reference. 
 As used in this Agreement, “business day” shall mean a day on which the NASDAQ Global Select Market (the “NASDAQ”) is
open for trading. The terms “herein,” “hereof,” “hereto,” “hereinafter” and similar terms, as used in this Agreement, shall in each case refer to this Agreement as a whole and not to any particular section,
paragraph, sentence or other subdivision of this Agreement. The term “or,” as used herein, is not exclusive. 
 The Company and the
Underwriters agree as follows: 
 1. Sale and Purchase. Upon the basis of the representations and warranties and subject to the other
terms and conditions herein set forth, the Company agrees to sell to the respective Underwriters, and each of the Underwriters, severally and not jointly, agrees to purchase from the Company, the aggregate principal amount of Firm Notes set forth
opposite the name of such Underwriter in Schedule A hereto, subject to adjustment in accordance with Section 8 hereof, in each case at a purchase price of 97% of the principal amount thereof (the “Purchase Price”). The
Company is advised by you that the Underwriters intend (i) to make a public offering of their respective portions of the Firm Notes as soon after the effectiveness of this Agreement as in your judgment is advisable and (ii) initially to
offer the Firm Notes upon the terms set forth in the Prospectus. 
 In addition, the
Company hereby grants to the several Underwriters the option (the “Over-Allotment Option”) to purchase, and upon the basis of the representations and warranties and subject to the other terms and conditions herein set forth, the
Underwriters shall have the right to purchase, severally and not jointly, from the Company, ratably in accordance with the aggregate principal amount of Firm Notes to be purchased by each of them, all or a portion of the Additional Notes solely to
cover over-allotments made in connection with the offering of the Firm Notes at the Purchase Price. This Over-Allotment Option may be exercised by the Representatives, on behalf of the several Underwriters, at any time and from time to time on or
before the thirtieth (30th) day following the date of the Prospectus Supplement by written notice to the
Company. Such notice shall set forth the aggregate principal amount of Additional Notes as to which the option is being exercised and the date and time when the Additional Notes are to be delivered (any such date and time being herein referred to as
an “additional time of purchase”); provided, however, that no additional time of purchase shall be (i) earlier than (a) the “time of purchase” (as defined below) or (b) the second business day
after the date on which the Over-Allotment Option shall have been exercised, or (ii) later than the tenth business day after the date on which the Over-Allotment Option shall have been exercised. The principal amount of Additional Notes to be
sold to each Underwriter shall be the principal amount which bears the same proportion to the aggregate principal amount of Additional Notes being purchased as the 

  

 - 3 - 

 
principal amount of Firm Notes set forth opposite the name of such Underwriter on Schedule A hereto bears to the aggregate principal amount of Firm
Notes, subject to adjustment in accordance with Section 8 hereof. 
 2. Payment and Delivery. Payment of the purchase price for
the Firm Notes shall be made to the Company by Federal Funds wire transfer, against delivery of the Firm Notes to you through the facilities of The Depository Trust Company (“DTC”) for the respective accounts of the Underwriters. Such
payment and delivery shall be made at 10:00 A.M., New York City time, on May 8, 2007 (unless another time shall be agreed to by you and the Company or unless postponed in accordance with the provisions of Section 8 hereof). The time at
which such payment and delivery are actually made is herein sometimes called the “time of purchase.” 
 Payment of the
purchase price for the Additional Notes, plus accrued interest, if any from the time of purchase to the additional time of purchase, shall be made at the additional time of purchase in the same manner and at the same office and time of day as the
payment for the Firm Notes. 
 Certificates for the Notes shall be in global form and registered in the names and in such denominations as
you shall request in writing prior to the time of purchase or the additional time of purchase, as the case may be. For the purpose of expediting the checking of the certificates for the Notes by you, the Company agrees to make such certificates
available to you for such purpose at least one full business day preceding the time of purchase or the additional time of purchase, as the case may be. 
 Deliveries of the documents described in Section 6 hereof with respect to the purchase of the Notes shall be made at the offices of Wilson Sonsini Goodrich & Rosati, Professional Corporation at 650 Page
Mill Road, Palo Alto, California, 94304 at 10:00 A.M., New York City time, on the date of the closing of the purchase of the Firm Notes or the Additional Notes, as the case may be. 
 3. Representations and Warranties of the Company. The Company represents and warrants to and agrees with each of the Underwriters that:

 (a) the Registration Statement has heretofore become effective under the Act or, with respect to any registration statement
to be filed to register the offer and sale of Notes and the Shares pursuant to Rule 462(b) under the Act, will be filed with the Commission and become effective under the Act no later than 10:00 P.M., New York City time, on the date hereof; no
stop order of the Commission preventing or suspending the use of any Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such
purpose have been instituted or, to the Company’s knowledge, have been threatened by the Commission; 
 (b) the
Registration Statement complied when it became effective, complies as of the date hereof and, as amended or supplemented, at the time of purchase, each additional time of purchase, if any, and at all times during which a prospectus is required by
the Act to be delivered (whether physically or through compliance with Rule 172 

  

 - 4 - 

 
under the Act or any similar rule) in connection with any sale of the Notes, will comply, in all material respects, with the requirements of the Act; the
Company is eligible to use a Form S-3 registration statement in connection with the offering and sale of the Notes and the Shares; the Registration Statement constitutes an “automatic shelf registration statement” (as defined in
Rule 405 under the Act); the Company has not received, from the Commission, a notice, pursuant to Rule 401(g)(2), of objection to the use of the automatic shelf registration statement form; as of the determination date applicable to the
Registration Statement (and any amendment thereof) and the offering contemplated hereby, the Company is a “well-known seasoned issuer” as defined in Rule 405 under the Act; the Registration Statement meets, and the offering and
sale of the Notes and the Shares as contemplated hereby complies with, the requirements of Rule 415 under the Act (including, without limitation, Rule 415(a)(5) under the Act); the Registration Statement did not, as of the Effective Time,
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; each Pre-Pricing Prospectus complied, at the time it was filed with the
Commission, and complies as of the date hereof, in all material respects with the requirements of the Act; at no time during the period that begins on the earlier of the date of such Pre-Pricing Prospectus and the date such Pre-Pricing Prospectus
was filed with the Commission and ends at the time of purchase did or will any Pre-Pricing Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading, and at no time during such period did or will any Pre-Pricing Prospectus, as then amended or supplemented, together with any combination of one or more
of the then issued Permitted Free Writing Prospectuses, if any, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading; each Basic Prospectus complied or will comply, as of its date and the date it was or will be filed with the Commission, complies as of the date hereof (if filed with the Commission on or prior to the date hereof) and, at
the time of purchase, each additional time of purchase, if any, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in
connection with any sale of the Notes, will comply, in all material respects, with the requirements of the Act; at no time during the period that begins on the earlier of the date of such Basic Prospectus and the date such Basic Prospectus was filed
with the Commission and ends at the time of purchase did or will any Basic Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading, and at no time during such period did or will any Basic Prospectus, as then amended or supplemented, together with any combination of one or more of the then
issued Permitted Free Writing Prospectuses, if any, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; each of the Prospectus Supplement and the Prospectus will comply, as of the date that it is filed with the Commission, the date of the Prospectus Supplement, the time of purchase, each 
  

 - 5 - 

 additional time of purchase, if any, and at all times during which a prospectus is required by the Act to
be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of the Notes, in all material respects, with the requirements of the Act (in the case of the Prospectus (including,
without limitation, Section 10(a) of the Act); at no time during the period that begins on the earlier of the date of the Prospectus Supplement and the date the Prospectus Supplement is filed with the Commission and ends at the later of the
time of purchase, the latest additional time of purchase, if any, and the end of the period during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar
rule) in connection with any sale of the Notes did or will any Prospectus Supplement or the Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; at no time during the period that begins on the date of any Permitted Free Writing Prospectus and ends at the time of purchase did or will such
Permitted Free Writing Prospectus include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided, however, that the Company makes no representation or warranty in this Section 3(b) with respect to any statement contained in the Registration Statement, any Pre-Pricing Prospectus, the Prospectus or any Permitted Free
Writing Prospectus in reliance upon and in conformity with information concerning an Underwriter and furnished in writing by or on behalf of such Underwriter through you to the Company expressly for use in the Registration Statement, such
Pre-Pricing Prospectus, the Prospectus or such Permitted Free Writing Prospectus; each Incorporated Document, at the time such document was filed, or will be filed, with the Commission or at the time such document became or becomes effective, as
applicable, complied or will comply, in all material respects, with the requirements of the Exchange Act and did not or will not, as applicable, include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; 
 (c) prior to
the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Notes by means of any “prospectus” (within the meaning of the Act) or used any “prospectus” (within the meaning of the Act) in
connection with the offer or sale of the Notes, in each case other than the Pre-Pricing Prospectuses and the Permitted Free Writing Prospectuses, if any; the Company has not, directly or indirectly, prepared, used or referred to any Permitted Free
Writing Prospectus except in compliance with Rule 163 or with Rules 164 and 433 under the Act; assuming that such Permitted Free Writing Prospectus is so sent or given after the Registration Statement was filed with the Commission (and
after such Permitted Free Writing Prospectus was, if required pursuant to Rule 433(d) under the Act, filed with the Commission), the sending or giving, by any Underwriter, of any Permitted Free Writing Prospectus will satisfy the provisions of Rule
164 and Rule 433 (without reliance on subsections (b), (c) and (d) of Rule 164); the conditions set forth in one or more of subclauses (i) through (iv), inclusive, of Rule 433(b)(1) under the Act are satisfied, and the
registration statement relating to the offering of the Notes contemplated hereby, as initially filed with the Commission, 

  

 - 6 - 

 
includes a prospectus that, other than by reason of Rule 433 or Rule 431 under the Act, satisfies the requirements of Section 10 of the Act;
neither the Company nor the Underwriters are disqualified, by reason of subsection (f) or (g) of Rule 164 under the Act, from using, in connection with the offer and sale of the Notes and the Shares, “free writing
prospectuses” (as defined in Rule 405 under the Act) pursuant to Rules 164 and 433 under the Act; the Company is not an “ineligible issuer” (as defined in Rule 405 under the Act) as of the eligibility determination date
for purposes of Rules 164 and 433 under the Act with respect to the offering of the Notes and the Shares contemplated by the Registration Statement; the parties hereto agree and understand that the content of any and all “road shows”
(as defined in Rule 433 under the Act) related to the offering of the Notes and the Shares contemplated hereby is solely the property of the Company; 
 (d) in accordance with Rule 2710(b)(7)(C)(i) of the National Association of Securities Dealers, Inc. (the “NASD”), the Notes have been registered with the Commission on Form S-3 under the Act pursuant
to the standards for such Form S-3 in effect prior to October 21, 1992; 
 (e) as of the date of this Agreement, the
Company has an authorized and outstanding capitalization as set forth in the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus under “Capitalization” and “Description of capital stock” (and any similar
sections or information, if any, contained in any Permitted Free Writing Prospectus), and, as of the time of purchase and any additional time of purchase, as the case may be, the Company shall have an authorized and outstanding capitalization as set
forth in the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus under “Capitalization” and “Description of capital stock” (and any similar sections or information, if any, contained in any Permitted Free
Writing Prospectus) (subject, in each case, to the issuance of shares of Common Stock upon exercise of stock options and warrants disclosed as outstanding in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus
and the Prospectus and the grant of options under existing stock option plans described in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus); all of the issued and outstanding shares of
capital stock, including the Common Stock, of the Company have been duly authorized and validly issued and are fully paid and non-assessable, have been issued in compliance with all applicable securities laws and were not issued in violation of any
statutory or preemptive right, resale right, right of first refusal or similar right (including, without limitation, any such rights in the Company’s certificate of incorporation or bylaws) except for such violations as would not result in a
Material Adverse Effect (as defined below); upon issuance, the Shares will be duly listed, and admitted and authorized for trading, on the Nasdaq Global Select Market (the “Share Exchange”); 
 (f) the Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of
Delaware, with full corporate power and authority to own, lease and operate its properties and conduct its business as described in the Disclosure Package to execute and deliver this Agreement, the Indenture and the Notes and to issue, sell and
deliver the Notes and the Shares as contemplated by this Agreement, the Indenture and the Notes; 
  

 - 7 - 

 (g) the Company is duly qualified to do business as a foreign corporation and is in good
standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate,
(i) have a material adverse effect on the business, properties, financial condition, results of operations or business prospects of the Company and the Subsidiaries (as hereinafter defined) taken as a whole, or (ii) prevent or materially
interfere with consummation of the transactions contemplated by this Agreement, the Indenture or the Notes (the occurrence of any such effect or any such prevention or interference or any such result described in the foregoing clauses (i), and
(ii) being herein referred to as a “Material Adverse Effect”); 
 (h) the Company has no significant
subsidiaries (as defined in Rule 1-02(w) of Regulation S-X) other than those identified in Exhibit 21 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2006 (collectively, the “Subsidiaries”); the
Company owns all of the issued and outstanding capital stock of each of the Subsidiaries, except to the extent required by local ownership requirements; other than the capital stock of the Subsidiaries, the Company does not own, directly or
indirectly, any shares of stock or any other equity or long-term debt securities of any corporation, firm, partnership, joint venture, association or other entity; complete and correct copies of the certificates of incorporation and the bylaws (or
other equivalent constitutive documents) of the Company and each Subsidiary and all amendments thereto have been made available to you, and no changes therein will be made on or after the date hereof through and including the time of purchase or, if
later, any additional time of purchase of the Notes; each Subsidiary has been duly incorporated or formed and is validly existing as a corporation or other business entity in good standing under the laws of the jurisdiction of its incorporation or
organization (to the extent the concept of “good standing” is recognized in such jurisdiction), with full corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the
Disclosure Package, except where the failure to be in good standing would not, individually or in the aggregate, have a Material Adverse Effect; each Subsidiary is duly qualified to do business as a foreign corporation and is in good standing in
each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, have a
Material Adverse Effect; each Subsidiary is in compliance in all respects with the laws, orders, rules, regulations and directives issued or administered by such jurisdictions, except where the failure to be in compliance would not, individually or
in the aggregate, have a Material Adverse Effect; and all of the outstanding shares of capital stock of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable, have been issued in compliance with all
applicable securities laws (including, without limitation, federal and state securities laws), were not issued in violation of any preemptive right, resale right, right of first refusal or similar right and are owned by the Company subject to no
security interest, other encumbrance or adverse claims; no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligation into shares of capital stock or ownership interests in the
Subsidiaries are outstanding, except where the existence of such rights would not, 

  

 - 8 - 

 
individually or in the aggregate, have a Material Adverse Effect; 
 (i) the execution and delivery of, and the performance by the Company of its obligations under, the Indenture have been duly and validly
authorized by all necessary corporate action on the part of the Company and, when executed and delivered by the Company, the Indenture will have been duly executed and delivered by the Company and, assuming due execution and delivery by the Trustee,
will constitute the legal, valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium
or other similar laws affecting creditors’ rights generally and by general principles of equity; on the Closing Date, the Indenture will be duly qualified under the Trust Indenture Act of 1939, as amended (the “TIA”); 
 (j) the Notes have been duly authorized by the Company and, when executed and delivered by the Company and duly authenticated in
accordance with the terms of the Indenture and delivered to and paid for by the Underwriters in accordance with the terms hereof, will constitute legal, valid and binding obligations of the Company, enforceable in accordance with their terms, except
as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity, and will be entitled to the benefits of the Indenture;
and will be convertible into the Shares in accordance with the Indenture; the Shares have been duly authorized and validly reserved for issuance upon conversion of the Notes based upon the initial conversion rate for the Notes, and, upon conversion
of the Notes in accordance with their terms and the terms of the Indenture, will be issued free of statutory and contractual preemptive rights, resale rights, rights of first refusal and similar rights and free of any voting restrictions (and will
be free of any restriction, pursuant to the Company’s certificate of incorporation or bylaws or any agreement or other instrument to which the Company is a party, upon the transfer thereof), and are sufficient in number to meet the current
conversion requirements (assuming all conditions to such conversion have been satisfied) based on the product of (i) the Conversion Rate (as defined in the Indenture) in effect as of the time of purchase and as of each additional time of
purchase and (ii) the aggregate principal amount of Notes to be outstanding immediately after such time of purchase or additional time of purchase, as applicable; such Shares, when so issued upon such conversion in accordance with the terms of
the Notes and of the Indenture, will be duly and validly issued and fully paid and nonassessable; 
 (k) the terms of the
Notes, the Indenture and the capital stock of the Company, including the Shares, conform in all material respects to the descriptions thereof contained in the Disclosure Package; 
 (l) this Agreement has been duly authorized, executed and delivered by the Company; 
 (m) neither the Company nor any of the Subsidiaries is in breach or violation of or in default under (nor has any event occurred which,
with notice, lapse of time or 

  

 - 9 - 

 
both, would result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s
behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (A) its respective certificate of incorporation or bylaws (or equivalent constitutive documents), (B) any indenture,
mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, (C) any license, lease, contract or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which any of them or
any of their respective properties may be bound or affected to the extent filed as an exhibit to the Company’s Annual Report on Form 10-K, (D) any federal, state, local or foreign law, regulation or rule, (E) any rule or regulation of
any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the rules and regulations of the NASDAQ), or (F) any decree, judgment or order applicable to the Company or any of the Subsidiaries
or any of their respective properties, except in the case of clauses (B) through (F) for breaches, defaults, or violations that individually or in the aggregate would not result in a Material Adverse Effect; 
 (n) the execution, delivery and performance of this Agreement, the Indenture and the Notes and the consummation of the transactions
contemplated hereby and thereby, including the issuance and sale of the Notes and the issuance of the Shares upon conversion of the Notes, will not conflict with, result in any breach or violation of or constitute a default under (nor constitute any
event which, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase,
redemption or repayment of all or a part of such indebtedness under) (or result in the creation or imposition of a lien, charge or encumbrance on any property or assets of the Company or any Subsidiary pursuant to), except where such conflict,
breach, violation or default would not result in a Material Adverse Effect (A) the certificate of incorporation or bylaws (or equivalent constitutive documents) of the Company or any Subsidiaries, (B) any indenture, mortgage, deed of
trust, bank loan or credit agreement or other evidence of indebtedness, (C) any license, lease, contract or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which any of them or any of their
respective properties may be bound or affected to the extent filed as an exhibit to the Company’s Annual Report on Form 10-K, (D) any federal, state, local or foreign law, regulation or rule, (E) any rule or regulation of any
self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the rules and regulations of the NASDAQ), or (F) any decree, judgment or order applicable to the Company or any of the Subsidiaries or
any of their respective properties, except in the case of clauses (B) through (F) for breaches, defaults, or violations that individually or in the aggregate would not result in a Material Adverse Effect; 
 (o) other than as set forth in the Disclosure Package, no approval, authorization, consent or order of or filing with (i) any
federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, (ii) any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the NASDAQ),
(iii) the stockholders of the Company or (iv) any other 

  

 - 10 - 

 
entity, is required in connection with the issuance and sale by the Company of the Notes or the issuance of Shares upon conversion of the Notes or the
consummation of the transactions as contemplated hereby and by the Indenture or the Notes, other than (i) registration of the offer and sale of the Notes and the Shares under the Act, which has been effected, (ii) qualification of the
Indenture under the TIA, which has been effected, (iii) the written consent of the requisite lenders pursuant to the Credit Agreement with KeyBank National Association, which has been obtained or (iv) any necessary qualification under the
securities or blue sky laws of the various jurisdictions in which the Notes are being offered by the Underwriters; 
 (p)
except where the failure to have them would not, individually or in the aggregate, have a Material Adverse Effect, each of the Company and the Subsidiaries has all necessary licenses, authorizations, consents and approvals and has made all necessary
filings required under any applicable federal, state, local or foreign law, regulation or rule, and has obtained all necessary licenses, authorizations, consents and approvals from other persons, in order to conduct their respective businesses;
neither the Company nor any of the Subsidiaries is in violation of, or in default under, or has received notice of any proceedings relating to revocation or modification of, any such license, authorization, consent or approval or any federal, state,
local or foreign law, regulation or rule or any decree, order or judgment applicable to the Company or any of the Subsidiaries, except where such violation, default, revocation or modification would not, individually or in the aggregate, have a
Material Adverse Effect; 
 (q) all legal or governmental proceedings, affiliate transactions, off-balance sheet
transactions, contracts, licenses, agreements, leases or documents of a character required to be described in the Disclosure Package, or to be filed as an exhibit to the Registration Statement have been so described in the Disclosure Package or the
documents incorporated by reference therein or filed as required; 
 (r) other than as described in the Disclosure Package,
there are no material actions, suits, claims, investigations or proceedings pending, or, to the Company’s knowledge, threatened to which the Company or any of the Subsidiaries or any of the Company’s directors or officers is or would be a
party or of which any of their respective properties is or would be subject at law or in equity, before or by any federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, or before or by any
self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the NASDAQ); 
 (s) Deloitte & Touche, LLP, whose report on the consolidated financial statements of the Company and the Subsidiaries is included or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses and the
Prospectus, are independent registered public accountants as required by the Act and by the rules of the Public Company Accounting Oversight Board; 
 (t) McGladrey & Pullen, LLP, whose report on the consolidated financial statements of the Company and the Subsidiaries is included or incorporated by reference in the Registration Statement, the Pre-Pricing
Prospectuses and the Prospectus, are 

  

 - 11 - 

 
independent registered public accountants as required by the Act and by the rules of the Public Company Accounting Oversight Board; 
 (u) the financial statements included or incorporated by reference in the Registration Statement and the Disclosure Package, together
with the related notes and schedules, present fairly in all material respects the consolidated financial position of the Company and the Subsidiaries as of the dates indicated, and the consolidated results of operations, cash flows and
stockholders’ equity of the Company and the Subsidiaries for the periods specified, and have been prepared in compliance with the requirements of the Act and Exchange Act and in conformity with U.S. generally accepted accounting principles
applied on a consistent basis during the periods involved; all pro forma financial statements or data included or incorporated by reference in the Registration Statement and the Disclosure Package, comply with the requirements of the Act and the
Exchange Act, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable, the pro forma adjustments used therein are appropriate to give effect to the transactions or circumstances described therein
and the pro forma adjustments have been properly applied to the historical amounts in the compilation of those statements and data; the other financial and statistical data contained or incorporated by reference in the Registration Statement and the
Disclosure Package, are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be
included or incorporated by reference in the Registration Statement, any Pre-Pricing Prospectus, or the Prospectus that are not included or incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities
or obligations, direct or contingent (including any off-balance sheet obligations), not disclosed in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus; and all disclosures contained or
incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and
regulations of the Commission) comply with Regulation G of the Exchange Act and/or Item 10 of Regulation S-K under the Act, as applicable; 
 (v) except as disclosed in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus, each stock option granted under any stock option plan of the Company or any
Subsidiary (each, a “Stock Plan”) was granted with a per share exercise price no less than the fair market value per share of Common Stock on the grant date of such option, and, except as would not result in a Material Adverse
Effect, no such grant involved any “back-dating,” “forward-dating” or similar practice with respect to the effective date of such grant; except as would not, individually or in the aggregate, have a Material Adverse Effect, each
such option (i) was granted in compliance with applicable law and with the applicable Stock Plan(s), (ii) was duly approved by the board of directors (or a duly authorized committee thereof) of the Company or such Subsidiary, as
applicable, and (iii) has been properly accounted for in the Company’s financial statements in accordance with U.S. generally accepted accounting principles and disclosed in the Company’s filings with the Commission; 
  

 - 12 - 

 (w) subsequent to the respective dates as of which information is given in the
Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, in each case excluding any amendments or supplements to the foregoing made after the execution of this Agreement, there has not
been (i) any material adverse change, or any development that is reasonably likely to result in a Material Adverse Effect, in the business, properties, management, financial condition or results of operations of the Company and the
Subsidiaries, (ii) any transaction that is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any
Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any change in the capital stock or outstanding indebtedness of the Company or any Subsidiaries, or (v) any dividend or distribution of any kind
declared, paid or made on the capital stock of the Company or any Subsidiary; 
 (x) the Company has obtained for the benefit
of the Underwriters the agreement (a “Lock-Up Agreement”), in the form set forth as Exhibit A hereto, of each of its directors and “officers” (within the meaning of Rule 16a-1(f) under the Exchange Act), each of
whom is identified in Exhibit A-1 hereto; 
 (y) neither the Company nor any Subsidiary is, upon the issuance and sale
of the Notes as contemplated herein, and the application of proceeds thereof, nor will the Company or any Subsidiary be “investment company” or an entity “controlled” by an “investment company,” as such terms are
defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”); 
 (z) the
Company, and each of the Subsidiaries, has good and marketable title to all material property (real and personal) described in the Disclosure Package as being owned by each of them, free and clear of all liens, claims, security interests or other
encumbrances; all the property described in the Disclosure Package, as being held under lease by the Company or a Subsidiary is held thereby under valid, subsisting and enforceable leases; 
 (aa) (i) the Company and the Subsidiaries own or can obtain on commercially reasonable terms, or have obtained valid and enforceable
licenses for, or other rights to use, the inventions, patent applications, patents, trademarks (both registered and unregistered), tradenames, service names, copyrights, trade secrets and other proprietary information described in the Registration
Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted, including
the commercialization of products or services described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, as under development, except where the failure to own, license
or have such rights would not, individually or in the aggregate, have a Material Adverse Effect (collectively, “Intellectual Property”); (ii) there are no third parties who have or, to the Company’s knowledge, will be able
to establish rights to any Intellectual Property, except for, and to the extent of, the ownership rights of the 

  

 - 13 - 

 
owners of the Intellectual Property which the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus, and the Prospectus
disclose is licensed to the Company; (iii) to the Company’s knowledge, there is no infringement by third parties of any Intellectual Property that would individually, or in the aggregate, have a Material Adverse Effect; (iv) there is
no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any Intellectual Property, except for such actions, suits, proceedings or claims as would not have
a Material Adverse Effect; (v) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company or any Subsidiary infringes or otherwise violates, or would, upon the
commercialization of the products or services described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, as under development, infringe or violate, any patent,
trademark, tradename, service name, copyright, trade secret or other proprietary rights of others, except for such actions, suits, proceedings or claims as would not have a Material Adverse Effect; (vi) the Company and the Subsidiaries have
complied in all material respects with the terms of any agreement pursuant to which Intellectual Property has been licensed to the Company or any Subsidiary, and all such agreements are in full force and effect; 
 (bb) no material labor dispute with the employees of the Company or any of the Subsidiaries exists, except as described in or
contemplated by Disclosure Package, or, to the knowledge of the Company, is imminent; 
 (cc) the Company and the
Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance
with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of
such permits, licenses or approvals would not, singly or in the aggregate, result in a Material Adverse Effect; 
 (dd) in
the ordinary course of its business, the Company, and each of the Subsidiaries, maintain insurance against such losses and risks and in such amounts as are customary in the businesses in which they are engaged; neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not
result in a Material Adverse Effect, except as described in or contemplated by the Disclosure Package; 
 (ee) neither the
Company nor any of the Subsidiaries has sustained since the date of the last audited financial statements included or incorporated by reference in the Registration Statement and the Disclosure Package, any material loss or interference with its
respective business from fire, explosion, flood or other calamity, whether or not 

  

 - 14 - 

 
covered by insurance, or from any labor dispute or court or governmental action, order or decree; 
 (ff) neither the Company nor any Subsidiary has sent or received any communication regarding termination of, or intent not to renew, any
of the contracts or agreements referred to or described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, or referred to or described in, or filed as an exhibit to the
Registration Statement or any Incorporated Document, and no such termination or non-renewal has been threatened by the Company or any Subsidiary or, to the Company’s knowledge, any other party to any such contract or agreement; 
 (gg) the Company maintains a system of internal control over financial reporting sufficient to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including those policies and procedures that (i) pertain to the maintenance of
records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and (iii) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements. 
 (hh) the Company has established and maintains and evaluates “disclosure controls and procedures” (as such term is defined in
Rule 13a-15 and 15d-15 under the Exchange Act) and “internal control over financial reporting” (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act); such disclosure controls and procedures are designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and
(ii) accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure; the Company’s independent auditors and the Audit Committee of the Board of Directors of the Company have been advised of, based on the Company’s most recent evaluation of its internal control over financial reporting:
(i) all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize
and report financial information; and (ii) all fraud, if any, whether or not material, that involves management or other employees who have a role in the Company’s internal control over financial reporting; since the date of the most
recent evaluation of such disclosure controls and procedures and internal control over financial reporting, there have been no significant changes in internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the 

  

 - 15 - 

 
Company’s internal control over financial reporting; the principal executive officers (or their equivalents) and principal financial officers (or their
equivalents) of the Company have made all certifications required by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and any related rules and regulations promulgated by the Commission, and the statements contained in any
such certification are complete and correct; the Company, the Subsidiaries and the Company’s directors and officers are each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules
and regulations of the Commission and the NASDAQ promulgated thereunder; 
 (ii) each “forward-looking statement”
(within the meaning of Section 27A of the Act or Section 21E of the Exchange Act) contained or incorporated by reference in the Disclosure Package, has been made or reaffirmed with a reasonable basis and has been disclosed in good faith;

 (jj) all statistical or market-related data included or incorporated by reference in the Disclosure Package, are based on
or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources to the extent required; 
 (kk) neither the Company nor any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or
affiliate of the Company or any of the Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the “Foreign Corrupt Practices Act”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or
authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the Foreign Corrupt Practices Act) or any
foreign political party or official thereof or any candidate for foreign political office, in contravention of the Foreign Corrupt Practices Act; and the Company, the Subsidiaries and, to the knowledge of the Company, its affiliates have conducted
their businesses in compliance with the Foreign Corrupt Practices Act and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith; 

(ll) no Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other
distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company or any other Subsidiary
of the Company, except as described in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus; 
 (mm) the Company is in compliance with the Marketplace Rules of the NASDAQ, including, without limitation, the requirements for continued designation of the Common Stock as a Nasdaq National Market security, and there
are no actions, suits 

  

 - 16 - 

 
or proceedings pending, threatened or, to the Company’s knowledge, contemplated, and the Company has not received any notice from the NASDAQ, regarding
the revocation of such designation or otherwise regarding the delisting of shares of Common Stock from the NASDAQ; 
 (nn)
except pursuant to this Agreement, neither the Company nor any of the Subsidiaries has incurred any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and delivery of this Agreement or
the consummation of the transactions contemplated hereby or by the Registration Statement; 
 (oo) neither the Company nor
any of the Subsidiaries nor any of their respective directors, officers, affiliates or controlling persons has taken, directly or indirectly, any action designed, or which has constituted or might reasonably be expected to cause or result in the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Notes or the Shares issuable upon conversion of the Notes; and 
 (pp) to the Company’s knowledge, there are no affiliations or associations
between any member of the NASD and the Company or any of the Company’s officers, directors or 5% or greater securityholders, or any beneficial owner of the Company’s unregistered equity securities that were acquired at any time on or after
the 180th day immediately preceding the date the Registration Statement was initially filed with the Commission.

 In addition, any certificate signed by any officer of the Company or any of the Subsidiaries and delivered to any Underwriter or counsel
for the Underwriters in connection with the offering of the Notes shall be deemed to be a representation and warranty by the Company or Subsidiary, as the case may be, as to matters covered thereby, to each Underwriter. 
 4. Certain Covenants of the Company. The Company hereby agrees with each of the Underwriters: 
 (a) to furnish such information as may be required and otherwise to cooperate in qualifying the Notes and the Shares for offering and sale
under the securities or blue sky laws of such states or other jurisdictions as you may designate and to maintain such qualifications in effect so long as you may request for the distribution of the Notes and the Shares; provided,
however, that the Company shall not be required to qualify as a foreign corporation or to consent to the service of process under the laws of any such jurisdiction (except service of process with respect to the offering and sale of the Notes
and the Shares); and to promptly advise you of the receipt by the Company of any notification with respect to the suspension of the qualification of the Notes and the Shares for offer or sale in any jurisdiction or the initiation or threatening of
any proceeding for such purpose; 
 (b) to make available to the Underwriters in New York City, as soon as reasonably
practicable after this Agreement becomes effective, and thereafter from time to time to furnish to the Underwriters, as many copies of the Prospectus (or of the 

  

 - 17 - 

 
Prospectus as amended or supplemented if the Company shall have made any amendments or supplements thereto after the effective date of the Registration
Statement) as the Underwriters may request for the purposes contemplated by the Act; in case any Underwriter is required to deliver (whether physically or through compliance with Rule 172 under the Act or any similar rule), in connection with the
sale of the Notes, a prospectus after the nine-month period referred to in Section 10(a)(3) of the Act, or after the time a post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation S-K under
the Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Act
or Item 512(a) of Regulation S-K under the Act, as the case may be; 
 (c) if, at the time this Agreement is executed
and delivered, it is necessary or appropriate for a post-effective amendment to the Registration Statement, or a Registration Statement under Rule 462(b) under the Act, to be filed with the Commission and become effective before the Notes may be
sold, the Company will use its best efforts to cause such post-effective amendment or such Registration Statement to be filed and become effective, and will pay any applicable fees in accordance with the Act, as soon as possible; and the Company
will advise you promptly and, if requested by you, will confirm such advice in writing, (i) when such post-effective amendment or such Registration Statement has become effective, and (ii) if Rule 430A under the Act is used, when the
Prospectus is filed with the Commission pursuant to Rule 424(b) under the Act (which the Company agrees to file in a timely manner in accordance with such Rules); 
 (d) if, at any time during the period when a prospectus is required by the Act to be delivered (whether physically or through compliance
with Rule 172 under the Act or any similar rule) in connection with any sale of Notes, the Registration Statement shall cease to comply with the requirements of the Act with respect to eligibility for the use of the form on which the Registration
Statement was filed with the Commission or the Registration Statement shall cease to be an “automatic shelf registration statement” (as defined in Rule 405 under the Act) or the Company shall have received, from the Commission, a notice,
pursuant to Rule 401(g)(2), of objection to the use of the form on which the Registration Statement was filed with the Commission, to (i) promptly notify you, (ii) promptly file with the Commission a new registration statement under the
Act, relating to the Notes and the Shares under the Act, or a post-effective amendment to the Registration Statement, which new registration statement or post-effective amendment shall comply with the requirements of the Act and shall be in a form
satisfactory to you, (iii) use its best efforts to cause such new registration statement or post-effective amendment to become effective under the Act as soon as practicable, (iv) promptly notify you of such effectiveness and (v) take
all other action necessary or appropriate to permit the public offering and sale of the Notes to continue as contemplated in the Prospectus; all references herein to the Registration Statement shall be deemed to include each such new registration
statement or post-effective amendment, if any; 
 (e) to advise you promptly, confirming such advice in writing, of any
request by the Commission for amendments or supplements to the Registration Statement, any 

  

 - 18 - 

 
Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing Prospectus or for additional information with respect thereto, or of notice of
institution of proceedings for, or the entry of a stop order, suspending the effectiveness of the Registration Statement and, if the Commission should enter a stop order suspending the effectiveness of the Registration Statement, to use its best
efforts to obtain the lifting or removal of such order as soon as possible; to advise you promptly of any proposal to amend or supplement the Registration Statement, any Pre-Pricing Prospectus or the Prospectus, and to provide you and
Underwriters’ counsel copies of any such documents for review and comment a reasonable amount of time prior to any proposed filing and to file no such amendment or supplement to which you shall object in writing; 
 (f) subject to Section 4(e) hereof, to use commercially reasonable efforts to file promptly all reports and documents and any
preliminary or definitive proxy or information statement required to be filed by the Company with the Commission in order to comply with the Exchange Act for so long as a prospectus is required by the Act to be delivered (whether physically or
through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Notes; and to provide you, for your review and comment, with a copy of such reports and statements and other documents to be filed by the Company
pursuant to Section 13, 14 or 15(d) of the Exchange Act during such period a reasonable amount of time prior to any proposed filing, and to file no such report, statement or document to which you shall have objected in writing; and to promptly
notify you of such filing; 
 (g) to pay the fees applicable to the Registration Statement in connection with the offering of
the Notes within the time required by Rule 456(b)(1)(i) under the Act (without reliance on the proviso to Rule 456(b)(1)(i) under the Act) and in compliance with Rule 456(b) and Rule 457(r) under the Act; 
 (h) to advise the Underwriters promptly of the happening of any event within the period during which a prospectus is required by the Act
to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Notes, which event could require the making of any change in the Prospectus then being used so that the
Prospectus would not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, and to advise the
Underwriters promptly if, during such period, it shall become necessary to amend or supplement the Prospectus to cause the Prospectus to comply with the requirements of the Act, and, in each case, during such time, subject to Section 4(e)
hereof, to prepare and furnish, at the Company’s expense, to the Underwriters promptly such amendments or supplements to such Prospectus as may be necessary to reflect any such change or to effect such compliance; 
 (i) to make generally available to its security holders, and to deliver to you, an earnings statement of the Company (which will satisfy
the provisions of Section 11(a) of the Act) covering a period of twelve months beginning after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act) as soon as is reasonably practicable after the termination
of such twelve-month period but in any case not later 

  

 - 19 - 

 
than May 1, 2008; 
 (j) to
furnish to you (one copy for each Representative and one copy for underwriters’ counsel) copies of the Registration Statement, as initially filed with the Commission, and of all amendments thereto (including all exhibits thereto and documents
incorporated by referenced therein) and sufficient copies of the foregoing (other than exhibits) for distribution of a copy to each of the other Underwriters. 
 (k) [reserved]; 
 (l) to apply the net proceeds from the sale of the Notes in a manner not inconsistent with the items set forth under the caption “Use of proceeds” in the Prospectus Supplement; 
 (m) to pay all costs, expenses, fees and taxes in connection with (i) the preparation and filing of the Registration Statement, each
Basic Prospectus, each Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus, each Permitted Free Writing Prospectus and any amendments or supplements thereto, and the printing and furnishing of copies of each thereof to the Underwriters
and to dealers (including costs of mailing and shipment), (ii) the registration, issue, sale and delivery of the Notes and the Shares including any stock or transfer taxes and stamp or similar duties payable upon the sale, issuance or delivery
of the Notes or the Shares, and all other costs related to the preparation, issuance, execution, authentication and delivery of the Notes and the Shares, (iii) the qualification of the Notes and the Shares for offering and sale under state or
foreign laws and the determination of their eligibility for investment under state or foreign law (including the reasonable legal fees and filing fees and other disbursements of counsel for the Underwriters) and the printing and furnishing of copies
of any blue sky surveys or legal investment surveys to the Underwriters and to dealers, (v) any listing of the Notes or the Shares on any securities exchange or qualification of the Shares for quotation on the NASDAQ and any registration
thereof under the Exchange Act, (vi) any filing for review of the public offering of the Notes and the Shares by the NASD, including the reasonable legal fees and filing fees and other disbursements of counsel to the Underwriters relating to
NASD matters, (vii) the fees and disbursements of any transfer agent or registrar for the Shares, (viii) the costs and expenses of the Company relating to presentations or meetings undertaken in connection with the marketing of the
offering and sale of the Notes and the Shares to prospective investors and the Underwriters’ sales forces, including, without limitation, expenses associated with the production of road show slides and graphics, reasonable fees and expenses of
any consultants engaged in connection with the road show presentations, travel, lodging and other expenses incurred by the officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show,
(ix) any fees payable to investment rating agencies with respect to the rating of the Notes; (x) the costs and charges of the Trustee and any transfer agent, registrar or depositary; (xi) the fees and expenses, if any, incurred in
connection with the admission of the Notes for trading in any appropriate market system, (xii) the costs and expenses of qualifying the Notes for inclusion in the book-entry settlement system of the DTC, (xiii) the fees, disbursements and
expenses of the Company’s counsel and the Company’s accountants in connection 

  

 - 20 - 

 
with the issuance and sale of the Notes and (xiv) the performance of the Company’s other obligations hereunder; 
 (n) to comply with Rule 433(d) under the Act (without reliance on Rule 164(b) under the Act) and with Rule 433(g) under the Act;

 (o) beginning on the date hereof and ending on, and including, the date that is 90 days after the date of the Prospectus
Supplement (the “Lock-Up Period”), without the prior written consent of the Representatives, not to (i) issue, sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of
or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act and the rules and regulations of the
Commission promulgated thereunder, with respect to, any Common Stock, any debt securities of the Company or any other securities of the Company that are substantially similar to Common Stock or the Notes, or any securities convertible into or
exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, (ii) file or cause to become effective a registration statement under the Act relating to the offer and sale of any Common Stock, any debt securities
of the Company or any other securities of the Company that are substantially similar to Common Stock or the Notes, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing,
(iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock, any debt securities of the Company or any other securities of the Company that are
substantially similar to Common Stock or the Notes, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, whether any such transaction is to be settled by delivery of
Common Stock or such other securities, in cash or otherwise or (iv) publicly announce an intention to effect any transaction specified in clause (i), (ii) or (iii), except, in each case, for (A) the issuance of the Notes as
contemplated by this Agreement, (B) the issuance of Shares upon conversion of the Notes, (C) issuances of Common Stock upon the exercise of options or warrants outstanding as of the date of this Agreement, and (D) the issuance of
employee stock options not exercisable during the Lock-Up Period or restricted stock pursuant to stock option plans, employment agreements or bonus plans existing on the date of this Agreement (or to be adopted by the shareholders at the 2007 annual
meeting of the Company) or the issuance of Common Stock pursuant to the Company’s employee stock purchase plan; provided, however, that if (a) during the period that begins on the date that is fifteen (15) calendar days
plus three (3) business days before the last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or (b) prior
to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on the last day of the Lock-Up Period, then the restrictions imposed by this Section 4(n)
shall continue to apply until the expiration of the date that is fifteen (15) calendar days plus three (3) business days after the date on which the issuance of the earnings release or the material news or material event occurs;

  

 - 21 - 

 (p) prior to the time of purchase, to issue no press release or other communication
directly or indirectly and hold no press conferences with respect to the Company or any Subsidiary, the financial condition, results of operations, business (outside of the ordinary course of business), material properties, material assets, or
material liabilities of the Company or any Subsidiary, or the offering of the Notes and the Shares, without your prior consent; and from the time of purchase to the additional time of purchase, if any, to issue no press release or other
communication directly or indirectly and hold no press conferences with respect to the Company or any Subsidiary, the financial condition, results of operations, business (outside of the ordinary course of business), material properties, material
assets, or material liabilities of the Company or any Subsidiary without first providing you, for your review and comment, a copy of such press release or other communication, and to make no such communication to which you shall have reasonably
objected in writing; 
 (q) not, at any time at or after the execution of this Agreement, to, directly or indirectly, offer
or sell any Notes or Shares by means of any “prospectus” (within the meaning of the Act), or use any “prospectus” (within the meaning of the Act) in connection with the offer or sale of the Notes or the Shares, in each case other
than the Prospectus; 
 (r) not to, at any time at or after the execution of this Agreement, directly or indirectly, offer or
sell any Notes or Shares by means of any written communication or use any written communication in connection with the offer or sale of the Notes or the Shares, in each case other than the Prospectus; 
 (s) not to, and to cause the Subsidiaries not to, take, directly or indirectly, any action designed, or which will constitute, or has
constituted, or might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Notes or the Shares; 
 (t) to use its commercially reasonable efforts to cause the Shares issuable upon conversion of the Notes to be listed on the NASDAQ and
to maintain such listing; 
 (u) to maintain a transfer agent and, if necessary under the jurisdiction of incorporation of
the Company, a registrar for the Common Stock; 
 (v) to reserve shares of Common Stock in an amount sufficient to satisfy
the Company’s obligations to issue Shares upon conversion of the Notes at the effective conversion rate of the Notes; and 
 (w) to (i) use its reasonable efforts to cause the Notes, and the Shares, to be included in the book-entry settlement system of the DTC and (ii) comply in all material respects with all of its obligations set forth in the
representations letter of the Company to the DTC relating to such inclusion. 
 5. Reimbursement of the Underwriters’ Expenses.
If the Notes are not delivered for any reason other than the termination of this Agreement pursuant to the fifth paragraph of 

  

 - 22 - 

 
Section 8 hereof or the default by one or more of the Underwriters in its or their respective obligations hereunder, the Company shall, in addition to
paying the amounts described in Section 4(k) hereof, reimburse the Underwriters for all of their out-of-pocket expenses, including the reasonable fees and disbursements of their counsel. 
 6. Conditions of the Underwriters’ Obligations. The several obligations of the Underwriters hereunder are subject to the accuracy of the
representations and warranties on the part of the Company on the date hereof, at the time of purchase, and if applicable at the additional time of purchase, the performance by the Company of its obligations hereunder and to the following additional
conditions precedent: 
 (a) The Company shall furnish to you at the time of purchase and, if applicable, at the additional
time of purchase, an opinion of Wilson Sonsini Goodrich & Rosati, counsel for the Company, addressed to the Underwriters, and dated the time of purchase or the additional time of purchase, as the case may be, in the form set forth in
Exhibit B hereto. 
 (b) You shall have received from Deloitte & Touche LLP letters dated, respectively, the
date of this Agreement, the date of the Prospectus Supplement, the time of purchase and, if applicable, the additional time of purchase, and addressed to the Underwriters (with executed copies for each of the Underwriters) in the forms satisfactory
to the Representatives, which letters shall cover, without limitation, the various financial disclosures contained in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free-Writing Prospectuses, if any.

 (c) You shall have received from McGladrey & Pullen, LLP letters dated, respectively, the date of this Agreement,
the date of the Prospectus Supplement, the time of purchase and, if applicable, the additional time of purchase, and addressed to the Underwriters (with executed copies for each of the Underwriters) in the forms satisfactory to the Representatives,
which letters shall cover, without limitation, the various financial disclosures contained in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free-Writing Prospectuses, if any. 
 (d) The Company shall furnish to you at the time of purchase and, if applicable, at the additional time of purchase, a secretary’s
certificate of John Ireland, General Counsel for the Company, addressed to the Underwriters, and dated the time of purchase or the additional time of purchase, as the case may be, in a form reasonably satisfactory to the Representatives. 

(e) The Company shall furnish to you at the time of purchase and, if applicable, at the additional time of purchase, an opinion of
Stibbe, Netherlands counsel for the Company, addressed to the Underwriters, and dated the time of purchase or the additional time of purchase, as the case may be, in the form set forth in Exhibit C hereto. 
 (f) The Company shall furnish to you at the time of purchase and, if applicable, at the additional time of purchase, an opinion of
Osborne Clarke, United Kingdom counsel for the Company, addressed to the Underwriters, and dated the time of 

  

 - 23 - 

 
purchase or the additional time of purchase, as the case may be, in the form set forth in Exhibit D hereto. 
 (g) You shall have received at the time of purchase and, if applicable, at the additional time of purchase, the favorable opinion of
Latham & Watkins LLP, counsel for the Underwriters, dated the time of purchase or the additional time of purchase, as the case may be, in form and substance reasonably satisfactory to the Representatives. 
 (h) No Prospectus or amendment or supplement to the Registration Statement or the Prospectus shall have been filed to which you shall
have reasonably objected in writing. 
 (i) The Registration Statement and any registration statement required to be filed,
prior to the sale of the Notes or the Shares, under the Act pursuant to Rule 462(b) shall have been filed and shall have become effective under the Act. The Prospectus Supplement shall have been filed with the Commission pursuant to Rule 424(b)
under the Act at or before 5:30 P.M., New York City time, on the second full business day after the date of this Agreement (or such earlier time as may be required under the Act). 
 (j) Prior to and at the time of purchase, and, if applicable, the additional time of purchase, (i) no stop order with respect to the
effectiveness of the Registration Statement shall have been issued under the Act or proceedings initiated under Section 8(d) or 8(e) of the Act; (ii) the Registration Statement and all amendments thereto shall not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; (iii) none of the Pre-Pricing Prospectuses or the Prospectus, and no amendment or
supplement thereto, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading; (iv) no
Disclosure Package, and no amendment or supplement thereto, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
are made, not misleading; and (v) none of the Permitted Free Writing Prospectuses, if any, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they are made, not misleading. 
 (k) The Company will, at the time of purchase and, if
applicable, at the additional time of purchase, deliver to you a certificate of its Chief Executive Officer and its Chief Financial Officer, dated the time of purchase or the additional time of purchase, as the case may be, in the form attached as
Exhibit E hereto. 
 (l) You shall have received copies, duly executed by the Company and the Trustee, of the
Indenture. 
 (m) You shall have received each of the signed Lock-Up Agreements referred to in Section 3(x) hereof, and
each such Lock-Up Agreement shall be in full force and 

  

 - 24 - 

 
effect at the time of purchase and the additional time of purchase, as the case may be. 
 (n) The Company shall have furnished to you such other documents and certificates as to the accuracy and completeness of any statement in
the Registration Statement, any Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing Prospectus as of the time of purchase and, if applicable, the additional time of purchase, as you may reasonably request. 
 (o) The Notes shall be included in the book-entry settlement system of the DTC, subject only to notice of issuance at or prior to the
time of purchase. 
 (p) There shall exist no event or condition which would constitute a default or an event of default
under the Notes or the Indenture. 
 (q) The NASD shall not have raised any objection with respect to the fairness or
reasonableness of the underwriting, or other arrangements of the transactions, contemplated hereby. 
 7. Effective Date of Agreement;
Termination. This Agreement shall become effective when the parties hereto have executed and delivered this Agreement. 
 The obligations
of the several Underwriters hereunder shall be subject to termination in the absolute discretion of the Representatives, if (1) since the time of execution of this Agreement or the earlier respective dates as of which information is given in
the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free-Writing Prospectuses, if any, there has been any change or any development involving a prospective change in the business, properties, management,
financial condition or results of operations of the Company and the Subsidiaries taken as a whole, the effect of which change or development is, in the judgment of the Representatives, so material and adverse as to make it impractical or inadvisable
to proceed with the public offering or the delivery of the Notes on the terms and in the manner contemplated in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free-Writing Prospectuses, if any, or
(2) since the time of execution of this Agreement, there shall have occurred: (A) a suspension or material limitation in trading in securities generally on the NYSE, the American Stock Exchange or the NASDAQ; (B) a suspension or
material limitation in trading in the Company’s securities on the NASDAQ; (C) a general moratorium on commercial banking activities declared by either federal or New York State authorities or a material disruption in commercial banking or
securities settlement or clearance services in the United States; (D) an outbreak or escalation of hostilities or acts of terrorism involving the United States or a declaration by the United States of a national emergency or war; or
(E) any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (D) or (E), in the sole judgment of the Representatives,
makes it impractical or inadvisable to proceed with the public offering or the delivery of the Notes on the terms and in the manner contemplated in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted
Free-Writing Prospectuses, if any, or (3) since the time of execution of this Agreement, there shall have occurred any downgrading, or any notice or announcement shall have been given or made of: (A) any intended or potential downgrading
or 

  

 - 25 - 

 
(B) any watch, review or possible change that does not indicate an affirmation or improvement in the rating accorded any securities of or guaranteed by the
Company or any Subsidiary by any “nationally recognized statistical rating organization,” as that term is defined in Rule 436(g)(2) under the Act. 
 If the Representatives elect to terminate this Agreement as provided in this Section 7, the Company and each other Underwriter shall be notified promptly in writing. 
 If the sale to the Underwriters of the Notes, as contemplated by this Agreement, is not carried out by the Underwriters for any reason permitted under
this Agreement, or if such sale is not carried out because the Company shall be unable to comply with any of the terms of this Agreement, the Company shall not be under any obligation or liability under this Agreement (except to the extent provided
in Sections 4(l), 5 and 9 hereof), and the Underwriters shall be under no obligation or liability to the Company under this Agreement (except to the extent provided in Section 9 hereof) or to one another hereunder. 
 8. Increase in Underwriters’ Commitments. Subject to Sections 6 and 7 hereof, if any Underwriter shall default in its obligation to take
up and pay for the Notes to be purchased by it hereunder at the time of purchase or an additional time of purchase (otherwise than for a failure of a condition set forth in Section 6 hereof or a reason sufficient to justify the termination of
this Agreement under the provisions of Section 7 hereof) (the “Defaulted Notes”) and if the aggregate principal amount of the Defaulted Notes which all Underwriters so defaulting shall have agreed but failed to take up and pay
for at such time does not exceed 10% of the total aggregate principal amount of Notes to be purchased at such time, the non-defaulting Underwriters (including the Underwriters, if any, substituted in the manner set forth below) shall take up and pay
for (in addition to the aggregate principal amount of Notes they are obligated to purchase at such time pursuant to Section 1 hereof) the aggregate principal amount of Defaulted Notes agreed to be purchased by all such defaulting Underwriters
at such time, as hereinafter provided. Such Defaulted Notes shall be taken up and paid for by such non-defaulting Underwriters, acting severally and not jointly, in such amount or amounts as you may designate with the consent of each
Underwriter so designated or, in the event no such designation is made, such Notes shall be taken up and paid for by all non-defaulting Underwriters pro rata in proportion to the aggregate principal amount of Firm Notes set forth opposite the names
of such non-defaulting Underwriters in Schedule A. 
 Without relieving any defaulting Underwriter from its obligations hereunder, the
Company agrees with the non-defaulting Underwriters that it will not sell any Firm Notes hereunder unless all of the Firm Notes are purchased by the Underwriters (or by substituted Underwriters selected by you with the approval of the Company or
selected by the Company with your approval). Without relieving any defaulting Underwriter from its obligations hereunder, the Company agrees with the non-defaulting Underwriters that it will not sell any Additional Notes hereunder at an
additional time of purchase unless all of the Additional Notes to be purchased by the Underwriters at such additional time of purchase (as set forth in the related written notice referred to in the second paragraph of Section 1 hereof) are
purchased by the Underwriters (or by substituted Underwriters selected by you with the approval of the Company or selected by the Company with your approval). 
  

 - 26 - 

 If a new Underwriter or Underwriters are substituted by the Underwriters or by the Company for a
defaulting Underwriter or Underwriters in accordance with the foregoing provision, the Company or you shall have the right to postpone the time of purchase for a period not exceeding five business days in order that any necessary changes in the
Registration Statement and the Prospectus and other documents may be effected. 
 The term “Underwriter” as used in this Agreement
shall refer to and include any Underwriter substituted under this Section 8 with like effect as if such substituted Underwriter had originally been named in Schedule A hereto. 
 If the aggregate principal amount of Defaulted Notes which the defaulting Underwriter or Underwriters agreed to purchase at the time of purchase or an
additional time of purchase, as the case may be, exceeds 10% of the total aggregate principal amount of Notes which all Underwriters agreed to purchase hereunder at such time, and if neither the non-defaulting Underwriters nor the Company shall make
arrangements within the five business day period stated above for the purchase of all the Firm Notes which the defaulting Underwriter or Underwriters agreed to purchase hereunder at such time, this Agreement, or, in the case of a default with
respect to any Additional Notes, the obligations of the Underwriters to purchase, and of the Company to sell, the Additional Notes that otherwise were to be purchased by the Underwriters at such additional time of purchase, shall terminate without
further act or deed and without any liability with respect thereto on the part of the Company to any Underwriter and without any liability with respect thereto on the part of any non-defaulting Underwriter to the Company; provided,
however, that, for avoidance of doubt, in the case of such a termination on account of a default with respect to any Additional Notes, this Agreement shall not terminate as to the Firm Notes or any Additional Notes purchased by the
Underwriters from the Company pursuant hereto prior to such termination. Nothing in this paragraph, and no action taken hereunder, shall relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement. 
 9. Indemnity and Contribution. 
 (a) The Company agrees to indemnify, defend and hold harmless each Underwriter, its partners, directors and officers, and any person who
controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and any “affiliate” within the meaning of Rule 405 under the Act) of such Underwriter, and the successors and assigns of all
of the foregoing persons, from and against any loss, damage, expense, liability or claim (including the reasonable cost of investigation) which, jointly or severally, any such Underwriter or any such person may incur under the Act, the Exchange Act,
the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or in the
Registration Statement as amended by any post-effective amendment thereof by the Company) or arises out of or is based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, except insofar as any such loss, damage, expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information
concerning 

  

 - 27 - 

 
such Underwriter furnished in writing by or on behalf of such Underwriter through you to the Company expressly for use in, the Registration Statement or
arises out of or is based upon any omission or alleged omission to state a material fact in the Registration Statement in connection with such information, which material fact was not contained in such information and which material fact was
required to be stated in such Registration Statement or was necessary to make such information not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any Prospectus (the term Prospectus for the
purpose of this Section 9 being deemed to include any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus and any amendments or supplements to the foregoing), in any Permitted Free Writing Prospectus, in any
“issuer information” (as defined in Rule 433 under the Act) of the Company or in any Prospectus together with any combination of one or more of the Permitted Free Writing Prospectuses, if any, or arises out of or is based upon any omission
or alleged omission to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except, with respect to such Prospectus or Permitted Free Writing
Prospectus, insofar as any such loss, damage, expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter
furnished in writing by or on behalf of such Underwriter through you to the Company expressly for use in, such Prospectus or Permitted Free Writing Prospectus or arises out of or is based upon any omission or alleged omission to state a material
fact in such Prospectus or Permitted Free Writing Prospectus in connection with such information, which material fact was not contained in such information and which material fact was necessary in order to make the statements in such information, in
the light of the circumstances under which they were made, not misleading. 
 (b) Each Underwriter severally agrees to
indemnify, defend and hold harmless the Company, its directors and officers, and any person who controls the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors and assigns of all of
the foregoing persons, from and against any loss, damage, expense, liability or claim (including the reasonable cost of investigation) which, jointly or severally, the Company or any such person may incur under the Act, the Exchange Act, the common
law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such
Underwriter furnished in writing by or on behalf of such Underwriter through you to the Company expressly for use in, the Registration Statement (or in the Registration Statement as amended by any post-effective amendment thereof by the Company), or
arises out of or is based upon any omission or alleged omission to state a material fact in such Registration Statement in connection with such information, which material fact was not contained in such information and which material fact was
required to be stated in such Registration Statement or was necessary to make such information not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information
concerning such Underwriter furnished in writing by or on behalf of such Underwriter through you to the Company expressly for use in, a Prospectus or a Permitted Free Writing Prospectus, or arises out of or is based upon any 

  

 - 28 - 

 
omission or alleged omission to state a material fact in such Prospectus or Permitted Free Writing Prospectus in connection with such information, which
material fact was not contained in such information and which material fact was necessary in order to make the statements in such information, in the light of the circumstances under which they were made, not misleading. 
 (c) If any action, suit or proceeding (each, a “Proceeding”) is brought against a person (an “indemnified
party”) in respect of which indemnity may be sought against the Company or an Underwriter (as applicable, the “indemnifying party”) pursuant to subsection (a) or (b), respectively, of this Section 9, such
indemnified party shall promptly notify such indemnifying party in writing of the institution of such Proceeding and such indemnifying party shall assume the defense of such Proceeding, including the employment of counsel reasonably satisfactory to
such indemnified party and payment of all fees and expenses; provided, however, that the omission to so notify such indemnifying party shall not relieve such indemnifying party from any liability which such indemnifying party may have
to any indemnified party, except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure to notify the indemnifying party. The indemnified party or parties shall have the
right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such indemnified party or parties unless the employment of such counsel shall have been authorized in writing by the
indemnifying party in connection with the defense of such Proceeding or the indemnifying party shall not have, within a reasonable period of time in light of the circumstances, employed counsel to defend such Proceeding or such indemnified party or
parties shall have reasonably concluded that there may be defenses available to it or them which are different from, additional to or in conflict with those available to such indemnifying party (in which case such indemnifying party shall not have
the right to direct the defense of such Proceeding on behalf of the indemnified party or parties, in any of which events such fees and expenses shall be borne by such indemnifying party and paid as incurred (it being understood, however, that such
indemnifying party shall not be liable for the expenses of more than one separate counsel (in addition to any local counsel) in any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties who are
parties to such Proceeding). The indemnifying party shall not be liable for any settlement of any Proceeding effected without its written consent but, if settled with its written consent, such indemnifying party agrees to indemnify and hold
harmless the indemnified party or parties from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel as contemplated by the second sentence of this Section 9(c), then the indemnifying party agrees that it shall be liable for any settlement of any Proceeding effected without its written
consent if (i) such settlement is entered into more than 60 business days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall not have fully reimbursed the indemnified party in accordance
with such request prior to the date of such settlement and (iii) such indemnified party shall have given the indemnifying party at least 30 days’ prior notice of its intention to settle. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement of any 

  

 - 29 - 

 
pending or threatened Proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by
such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such Proceeding and does not include an admission of fault or culpability or any
failure to act by or on behalf of such indemnified party. 
 (d) If the indemnification provided for in this Section 9
is unavailable to an indemnified party under subsections (a) and (b) of this Section 9 or insufficient to hold an indemnified party harmless in respect of any losses, damages, expenses, liabilities or claims referred to therein, then
each applicable indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party as a result of such losses, damages, expenses, liabilities or claims (i) in such proportion as is appropriate to reflect the
relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Notes or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection with the statements or omissions which
resulted in such losses, damages, expenses, liabilities or claims, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in
the same respective proportions as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the
Underwriters, bear to the aggregate public offering price of the Notes (before deducting underwriting discounts and commissions and other expenses). The relative fault of the Company on the one hand and of the Underwriters on the other shall be
determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates to information supplied by the Company or by the Underwriters and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, damages, expenses, liabilities and claims referred to in this
subsection shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating, preparing to defend or defending any Proceeding. 
 (e) The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 9 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in subsection
(d) above. Notwithstanding the provisions of this Section 9, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Notes underwritten by such Underwriter and
distributed to the public were offered to the public exceeds the amount of any damage which such Underwriter has otherwise been required to pay by reason of such untrue statement or alleged untrue statement or omission or alleged omission. No
person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to 

  

 - 30 - 

 
contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this
Section 9 are several in proportion to the respective principal amount of Notes they have agreed to purchase hereunder and not joint. 
 (f) The indemnity and contribution agreements contained in this Section 9 and the covenants, warranties and representations of the Company contained in this Agreement shall remain in full force and effect
regardless of any investigation made by or on behalf of any Underwriter, its partners, directors or officers or any person (including each partner, officer or director of such person) who controls any Underwriter within the meaning of
Section 15 of the Act or Section 20 of the Exchange Act, or by or on behalf of the Company, its directors or officers or any person who controls the Company within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act, and shall survive any termination of this Agreement or the issuance and delivery of the Notes. The Company and each Underwriter agree promptly to notify each other of the commencement of any Proceeding against it and, in the case
of the Company, against any of the Company’s officers or directors in connection with the issuance and sale of the Notes, or in connection with the Registration Statement, any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus or any
Permitted Free Writing Prospectus. 
 10. Information Furnished by the Underwriters. The statements set forth under (i) the
subheading “Commissions and Discounts” under the caption “Underwriting” in the Prospectus, only insofar as such statements relate to the amount of the selling concession and reallowance, and (ii) the subheading “Price
Stabilization, Short Positions” under the caption “Underwriting” in the Prospectus, only insofar as such statements relate to over-allotment and stabilization activities that may be undertaken by the Underwriters, constitute the only
information furnished by or on behalf of the Underwriters as such information is referred to in Sections 3 and 9 hereof. 
 11. Tax
Disclosure. Notwithstanding any other provision of this Agreement, from the commencement of discussions with respect to the transactions contemplated hereby, the Company (and each employee, representative or other agent of the Company) may
disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure (as such terms are used in Sections 6011, 6111 and 6112 of the U.S. Code and the Treasury Regulations promulgated thereunder) of the transactions
contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided relating to such tax treatment and tax structure. 
 12. Notices. Except as otherwise herein provided, all statements, requests, notices and agreements shall be in writing or by telegram or facsimile
and, if to the Underwriters, shall be sufficient in all respects if delivered or sent to UBS Securities LLC, 299 Park Avenue, New York, NY 10171-0026, Attention: Syndicate Department and, if to the Company, shall be sufficient in all respects if
delivered or sent to the Company at the offices of the Company at 18000 Von Karman Ave., Irvine, CA 92612, Tel (949) 585-4000, Attention: General Counsel. 
 13. Governing Law; Construction. This Agreement and any claim, counterclaim or dispute of any kind or nature whatsoever arising out of or in any way relating to this Agreement (“Claim”),
directly or indirectly, shall be governed by, and construed in accordance with, the 

  

 - 31 - 

 
laws of the State of New York. The section headings in this Agreement have been inserted as a matter of convenience of reference and are not a part of this
Agreement. 
 14. Submission to Jurisdiction. Except as set forth below, no Claim may be commenced, prosecuted or continued in any
court other than the courts of the State of New York located in the City and County of New York or in the United States District Court for the Southern District of New York, which courts shall have jurisdiction over the adjudication of such matters,
and the Company consents to the jurisdiction of such courts and personal service with respect thereto. The Company hereby consents to personal jurisdiction, service and venue in any court in which any Claim arising out of or in any way relating to
this Agreement is brought by any third party against any Underwriter or any indemnified party. Each Underwriter and the Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) waives all
right to trial by jury in any action, proceeding or counterclaim (whether based upon contract, tort or otherwise) in any way arising out of or relating to this Agreement. The Company agrees that a final judgment in any such action, proceeding or
counterclaim brought in any such court shall be conclusive and binding upon the Company and may be enforced in any other courts to the jurisdiction of which the Company is or may be subject, by suit upon such judgment. 
 15. Parties at Interest. The Agreement herein set forth has been and is made solely for the benefit of the Underwriters and the Company and to the
extent provided in Section 9 hereof the controlling persons, partners, directors, officers and affiliates referred to in such Section, and their respective successors, assigns, heirs, personal representatives and executors and administrators.
No other person, partnership, association or corporation (including a purchaser, as such purchaser, from any of the Underwriters) shall acquire or have any right under or by virtue of this Agreement. 
 16. No Fiduciary Relationship. The Company hereby acknowledges that the Underwriters are acting solely as underwriters in connection with the
purchase and sale of the Company’s securities. The Company further acknowledges that the Underwriters are acting pursuant to a contractual relationship created solely by this Agreement entered into on an arm’s length basis, and in no event
do the parties intend that the Underwriters act or be responsible as a fiduciary to the Company, its management, stockholders, creditors or any other person in connection with any activity that the Underwriters may undertake or have undertaken in
furtherance of the purchase and sale of the Company’s securities, either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary or similar obligations to the Company, either in connection with the transactions
contemplated by this Agreement or any matters leading up to such transactions, and the Company hereby confirms its understanding and agreement to that effect. The Company and the Underwriters agree that they are each responsible for making their own
independent judgments with respect to any such transactions and that any opinions or views expressed by the Underwriters to the Company regarding such transactions, including, but not limited to, any opinions or views with respect to the price or
market for the Company’s securities, do not constitute advice or recommendations to the Company. The Company and the Underwriters agree that the Underwriters are acting as principal and not the agent or fiduciary of the Company and no
Underwriter has assumed, and none of them will assume, any advisory responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether any 

  

 - 32 - 

 
Underwriter has advised or is currently advising the Company on other matters). The Company hereby waives and releases, to the fullest extent permitted by
law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of any fiduciary or similar duty to the Company in connection with the transactions contemplated by this Agreement or any matters leading
up to such transactions. 
 17. Counterparts. This Agreement may be signed by the parties in one or more counterparts which together
shall constitute one and the same agreement among the parties. 
 18. Successors and Assigns. This Agreement shall be binding upon the
Underwriters and the Company and their successors and assigns and any successor or assign of any substantial portion of the Company’s and any of the Underwriters’ respective businesses and/or assets. 
 19. Miscellaneous. UBS, an indirect, wholly owned subsidiary of UBS AG, is not a bank and is separate from any affiliated bank, including any U.S.
branch or agency of UBS AG. Because UBS is a separately incorporated entity, it is solely responsible for its own contractual obligations and commitments, including obligations with respect to sales and purchases of securities. Securities sold,
offered or recommended by UBS are not deposits, are not insured by the Federal Deposit Insurance Corporation, are not guaranteed by a branch or agency, and are not otherwise an obligation or responsibility of a branch or agency. 
 [The Remainder of This Page Intentionally Left Blank; Signature Page Follows] 
  

 - 33 - 

 If the foregoing correctly sets forth the understanding between the Company and the several Underwriters,
please so indicate in the space provided below for that purpose, whereupon this Agreement and your acceptance shall constitute a binding agreement between the Company and the Underwriters, severally. 
  

			
	Very truly yours,
	
	EPICOR SOFTWARE CORPORATION
		
	By:	 	/s/ MICHAEL PIRAINO
		
	Name:	 	Michael Piraino
		
	Title:	 	Executive Vice President and Chief Financial Officer

 Accepted and agreed to as of the date 
 first above written, on behalf of itself 
 and the other several Underwriters 
 named in Schedule A hereto: 
  

			
	UBS SECURITIES LLC
		
	By:	 	/s/ JOHN JOLIET
	Name:	 	John Joliet
	Title:	 	Managing Director
		
	By:	 	/s/ JOHN C. WADSWORTH
	Name:	 	John C. Wadsworth
	Title:	 	Managing Director
	
	LEHMAN BROTHERS INC.
		
	By:	 	/s/ MICHAEL HRYNUIK
	Name:	 	Michael Hrynuik
	Title:	 	Senior Vice President

 SCHEDULE A 
  

				
	 Underwriters
	  	Principal Amount
of Firm Notes
	 UBS SECURITIES LLC
	  	$	80,000,000
	 LEHMAN BROTHERS INC
	  	$	80,000,000
	 COWEN AND COMPANY, LLC
	  	$	16,000,000
	 NEEDHAM & COMPANY, LLC
	  	$	12,000,000
	 PIPER JAFFRAY & CO.
	  	$	12,000,000
		  	 	 
	 Total
	  	$	200,000,000
		  	 	 

  

 SCHEDULE B 
  

			
	1.	  	Preliminary term sheet, dated May 1, 2007
	2.	  	Press release relating to the announcement of the proposed offering, dated May 1, 2007
	3.	  	Final term sheet, dated May 2, 2007
	4.	  	Press release relating to the pricing of the Notes, dated May 2, 2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]